While multidrug resistance (MDR) in cancer is well established, little is known about the
cellular pathways regulating the expression and trafficking of the MDR efflux transporter like …

Background BCRP/ABCG2 emerged as an important multidrug resistance protein, because
it confers resistance to several classes of cancer chemotherapeutic agents and to a number …

Erlotinib was originally developed as an epidermal growth factor receptor (EGFR)-specific
inhibitor for the treatment of solid malignancies, yet also exerts significant EGFR …

Cellular responses toward cytotoxic drugs are influenced by crosstalk between oncogenic
signals and resistance mechanisms. Inhibition of the PI3K/Akt pathway is effective in …

Purpose: To study the role of drug transporters in central nervous system (CNS) penetration
and cellular accumulation of erlotinib and its metabolite, OSI-420. Experimental Design …

Background: It has been previously shown that gefitinib reverses breast cancer resistance
protein (BCRP)-mediated drug resistance. Here, the impact of BCRP on gefitinib-mediated …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) inhibit the function
of certain adenosine triphosphate (ATP)‐binding cassette transporters, including P …

ABCG2 is a potential biomarker causing multidrug resistance (MDR) in Non-Small Cell Lung
Cancer (NSCLC). We conducted this study to investigate whether Icotinib, a small-molecule …

Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI),
is used clinically as first-line therapy in patients with advanced non-small cell lung cancer …

Purpose: Breast cancer resistance protein (BCRP) confers resistance against
topoisomerase I inhibitors in cancer cells. Very recently, we reported that gefitinib reverses …